Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of subcutaneous CT-P13 maintenance therapy in moderately to severely active Crohn's disease
MOH_2019-08-15_007347Phase 3Recruiting
- Sponsor
- Celltrion
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing CT-P13 subcutaneous with Placebo subcutaneous (2 arms). Started Jul 2019; status: recruiting.
02
Drugs
infliximab-dyyb
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2019-08-15_007347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-08-15_007347.